Search results for "Rechallenge"

showing 2 items of 2 documents

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib

2018

Background: Rechallenge with imatinib is an option in advanced gastrointestinal stromal tumor (GIST) patients following progression with standard tyrosine-kinase inhibitors (TKIs), imatinib, sunitinib and regorafenib. We retrospectively collected data from metastatic Italian GIST patients treated with imatinib resumption after progression to conventional TKIs. Methods: A total of 104 eligible advanced GIST patients, previously treated with imatinib, sunitinib and regorafenib, were collected from six referral Italian institutions. Mutational analysis was recorded and correlated with survival and response according to RECIST 1.1 or CHOI criteria. Results: Overall, 71 patients treated with ima…

0301 basic medicineOncologymedicine.medical_specialtyStromal cellrechallengelcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineRegorafenibhemic and lymphatic diseasesmedicineIn patientStromal tumorneoplasmsOriginal ResearchGiSTbusiness.industrySunitinibImatiniblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensexon 11 KIT mutationTKI030104 developmental biologyOncologychemistryexon 11 KIT mutation; GIST; imatinib; rechallenge; TKIimatinib030220 oncology & carcinogenesisbusinessGIST; TKI; exon 11 KIT mutation; imatinib; rechallengemedicine.drugGIST
researchProduct

Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports

2021

Treatment with immune checkpoint inhibitors (ICIs) can be complicated by cardiovascular toxicity, including pericardial disease. To date, no prospective studies specifically investigated the optimal treatment of ICI-associated pericardial disease, and the available evidence is based on case reports and series only. We performed a systematic review of case reports and series including 20 publications for a total of 28 cases of ICI-associated pericardial disease. In this review, pericardial disease was reversible in the majority of cases (75%), although 2 deaths were reported. The majority of cases were life-threatening (G4, 53.6%) or severe (G3, 21.4%), requiring pericardiocentesis. Higher r…

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyPericardial effusionRechallengePericardial effusion03 medical and health sciencesPericarditisImmune checkpoint inhibitors0302 clinical medicineCardiac tamponademedicineImmunology and AllergyPericarditisHumansAdverse effectCardiac tamponadebusiness.industrymedicine.diseaseCardiotoxicityDiscontinuationPericardial windowSurgeryOncologyEffusionPericardiocentesisbusiness030215 immunology
researchProduct